Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04395677 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: AnHeart Therapeutics Inc. to Nuvation Bio Inc. Primary completion date changed from estimate of Dec 30, 2023 to Jun 7, 2024 · Completion date: Dec 31, 2025 to Jun 2027 · Study description shortened, about 13 wordsv6 Show 3 more changesShow less
    • Primary completion date changed from estimate of Dec 30, 2023 to Jun 7, 2024
    • Completion date: Dec 31, 2025 to Jun 2027
    • Study description shortened, about 13 words

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 106 to 173 Trial status: Recruiting to Active, Not Recruiting · Study description shortened, about 21 words · Site details revised · 1 morev5 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study description shortened, about 21 words
    • Site details revised
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv4
  4. Primary completion date: Dec 30, 2022 to Dec 30, 2023v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Primary completion date: Sep 30, 2022 to Dec 30, 2022 · Start date changed from estimate of Jun 30, 2020 to Jul 7, 2020v2 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Sep 30, 2022 to Dec 30, 2022
    • Start date changed from estimate of Jun 30, 2020 to Jul 7, 2020
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
Trial Details
NCT Number NCT04395677
Lead Sponsor Nuvation Bio Inc.
Conditions Non Small Cell Lung Cancer
Enrollment 173 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov